source
- Verastem makes its stand as a RevMed competitor in pancreatic cancerVerastem Oncology had a big Wednesday morning: It announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massac…
- Gilead signs $1.9 billion deal with Vir Biotechnology to license dual-masked T-cell engagers for oncologyGilead Sciences announced a licensing agreement with Vir Biotechnology to access Vir's dual-masked PRO-XTEN T-cell engager platform for oncology. Under the deal, Vir will discover, design and opti…